Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P22077 is a cell-permeable, small molecule inhibitor of the deubiquitinating enzyme USP7 (Ubiquitin-Specific Protease 7), also known as HAUSP (Herpesvirus-Associated Ubiquitin-Specific Protease). It was one of the first relatively selective USP7 inhibitors identified and is widely used as a chemical probe in preclinical research. By inhibiting USP7, P22077 prevents the deubiquitination and subsequent stabilization of MDM2, leading to MDM2 degradation and the stabilization of the tumor suppressor p53. This mechanism induces p53-mediated apoptosis and growth arrest in various cancer cell lines. Research has demonstrated its potential in treating glioblastoma by targeting glioma stem cells (GSCs), as well as in neuroblastoma and other p53-dependent malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on P22077.